Ventyx Biosciences Inc (VTYX) concluded trading on Wednesday at a closing price of $2.25, with 5.4 million shares of worth about $12.15 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.79% during that period and on January 08, 2025 the price saw a loss of about -10.71%. Currently the company’s common shares owned by public are about 70.67M shares, out of which, 52.89M shares are available for trading.
Stock saw a price change of 2.74% in past 5 days and over the past one month there was a price change of -27.88%. Year-to-date (YTD), VTYX shares are showing a performance of 2.74% which decreased to -13.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.67 but also hit the highest price of $11.48 during that period. The average intraday trading volume for Ventyx Biosciences Inc shares is 1.52 million. The stock is currently trading -4.50% below its 20-day simple moving average (SMA20), while that difference is down -1.78% for SMA50 and it goes to -23.66% lower than SMA200.
Ventyx Biosciences Inc (NASDAQ: VTYX) currently have 70.67M outstanding shares and institutions hold larger chunk of about 63.96% of that.
The stock has a current market capitalization of $159.10M and its 3Y-monthly beta is at 0.54. It has posted earnings per share of -$2.37 in the same period. It has Quick Ratio of 23.52 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VTYX, volatility over the week remained 10.44% while standing at 9.13% over the month.
Stock’s fiscal year EPS is expected to rise by 36.44% while it is estimated to increase by 4.18% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on March 12, 2024 offering an Overweight rating for the stock and assigned a target price range of between $7 and $16 to it. Coverage by Oppenheimer stated Ventyx Biosciences Inc (VTYX) stock as an Outperform in their note to investors on March 12, 2024, suggesting a price target of $12 for the stock. On November 07, 2023, Wells Fargo Downgrade their recommendations, while on November 07, 2023, Stifel Downgrade their ratings for the stock with a price target of $6. Stock get a Perform rating from Oppenheimer on November 07, 2023.
